IDF President-elect Meets Union Minister Jitendra Singh on Boosting Indigenous Biosimilar Insulin & Diabetes Device Production

The President‑elect of the International Diabetes Federation met Union Minister Dr Jitendra Singh to discuss scaling up India’s indigenous biosimilar insulin and low‑cost diabetes device production, citing global supply risks as multinational firms shift to newer therapies. The dialogue underscores the need for policy, regulatory and industry support to ensure affordable diabetes care, a priority for UPSC aspirants across health, economy and technology domains.

Overview The IDF President‑elect Dr Niti Pall visited India and met Union Minister Dr Jitendra Singh , who also heads the Ministry of Science & Technology. The dialogue centred on expanding India’s capacity to manufacture biosimilar insulin and related diabetes technologies such as CGM systems. Key Developments Minister Singh highlighted the strategic need to scale up domestic insulin production amid global supply concerns, noting that multinational firms are shifting focus to newer GLP‑1 drugs . The Department of Biotechnology ( DBT ) is already backing an Indian company to expand insulin‑manufacturing capacity. Both sides agreed to explore collaborations in clinical trials, technology development and financing models, with a stakeholder meeting proposed for July during Dr Pall’s next visit. Discussion extended to affordable diabetes devices, noting China’s low‑cost CGM and insulin‑pump market share and urging Indian firms to match this capability. Important Facts • India bears one of the world’s highest diabetes burdens, with an estimated 77 million diabetics (2026). • Global insulin supply is concentrated among a handful of multinational companies, creating vulnerability in the insulin supply chain . • Biosimilar insulin can reduce treatment cost by 30‑50% compared with branded products. • Low‑cost CGM devices from China are priced 40‑60% lower than Western equivalents, accelerating their market penetration. UPSC Relevance Understanding India’s push for indigenous biosimilar insulin links directly to GS1 (Health & Social Issues) – the challenge of affordable healthcare for a large diabetic population. The role of the DBT illustrates inter‑ministerial coordination, relevant for GS3 (Science & Technology) . The discussion on supply‑chain concentration and price‑affordability touches upon GS3 (Economy) and the need for self‑reliance (Atmanirbhar Bharat). Finally, the proposed stakeholder platform reflects governance and public‑private partnership concepts covered in GS2 (Polity) . Way Forward 1. Policy Support: Formulate a dedicated National Biosimilar Insulin Mission with incentives for R&D, technology transfer and capacity building. 2. Regulatory Streamlining: Accelerate approval pathways for biosimilar insulin and indigenous CGM devices through the Central Drugs Standard Control Organization (CDSCO). 3. Industry Collaboration: Encourage joint ventures between Indian pharma firms and global biotech players to access know‑how. 4. Financing Mechanisms: Set up a fund under the DBT to support scale‑up of manufacturing units and subsidise low‑cost device production. 5. Stakeholder Engagement: Organise the July meeting with researchers, industry, patient groups and international agencies to chart a roadmap for affordable diabetes care.

<h2>Overview</h2> The IDF President‑elect Dr Niti Pall visited India and met Union Minister Dr Jitendra Singh, who also heads the Ministry of Science & Technology. The dialogue centred on expanding India’s capacity to manufacture <span class="key-term" data-definition="Biosimilar insulin — a biologic product highly similar to an existing insulin brand, offering comparable safety and efficacy at lower cost, crucial for affordable diabetes care (GS1: Health)">biosimilar insulin and related diabetes technologies such as CGM systems. <h2>Key Developments</h2> <ul> <li>Minister Singh highlighted the strategic need to scale up domestic insulin production amid global supply concerns, noting that multinational firms are shifting focus to newer GLP‑1 drugs.</li> <li>The Department of Biotechnology (<span class="key-term" data-definition="Department of Biotechnology (DBT) — a wing of the Ministry of Science & Technology that funds and supports biotech research, innovation and manufacturing in India (GS3: Science & Technology)">DBT) is already backing an Indian company to expand insulin‑manufacturing capacity.</li> <li>Both sides agreed to explore collaborations in clinical trials, technology development and financing models, with a stakeholder meeting proposed for July during Dr Pall’s next visit.</li> <li>Discussion extended to affordable diabetes devices, noting China’s low‑cost CGM and insulin‑pump market share and urging Indian firms to match this capability.</li> </ul> <h2>Important Facts</h2> • India bears one of the world’s highest diabetes burdens, with an estimated 77 million diabetics (2026). • Global insulin supply is concentrated among a handful of multinational companies, creating vulnerability in the insulin supply chain. • Biosimilar insulin can reduce treatment cost by 30‑50% compared with branded products. • Low‑cost CGM devices from China are priced 40‑60% lower than Western equivalents, accelerating their market penetration. <h2>UPSC Relevance</h2> Understanding India’s push for indigenous biosimilar insulin links directly to GS1 (Health & Social Issues) – the challenge of affordable healthcare for a large diabetic population. The role of the <span class="key-term" data-definition="Department of Biotechnology (DBT) — a wing of the Ministry of Science & Technology that funds and supports biotech research, innovation and manufacturing in India (GS3: Science & Technology)">DBT illustrates inter‑ministerial coordination, relevant for GS3 (Science & Technology). The discussion on supply‑chain concentration and price‑affordability touches upon GS3 (Economy) and the need for self‑reliance (Atmanirbhar Bharat). Finally, the proposed stakeholder platform reflects governance and public‑private partnership concepts covered in GS2 (Polity). <h2>Way Forward</h2> 1. Policy Support: Formulate a dedicated National Biosimilar Insulin Mission with incentives for R&D, technology transfer and capacity building. 2. Regulatory Streamlining: Accelerate approval pathways for biosimilar insulin and indigenous CGM devices through the Central Drugs Standard Control Organization (CDSCO). 3. Industry Collaboration: Encourage joint ventures between Indian pharma firms and global biotech players to access know‑how. 4. Financing Mechanisms: Set up a fund under the DBT to support scale‑up of manufacturing units and subsidise low‑cost device production. 5. Stakeholder Engagement: Organise the July meeting with researchers, industry, patient groups and international agencies to chart a roadmap for affordable diabetes care.

Key Facts

Background & Context

UPSC Syllabus Connections

Mains Answer Angle

Full Article

Practice Questions

Prelims MCQ

Mains Short Answer

Mains Essay